Thats why we ended the partnership. In a post on X, Hims Chief Executive Andrew Dudum called the Novo executives comments misleading. He said Novo had been pressuring Hims to steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed, he said, adding that Hims will continue to offer a range of treatments, including Wegovy. Hims shares tumbled 35% in New York Monday the most ever as analysts said the withdrawal would leave the telehealth company without an attractive obesity profit stream
If your prescriber approves you for a B12/MIC prescription, its up to you how long you stick with it
Thus, GLP-1 receptors are currently one of the most coveted targets to treat type 2 diabetes as it can reduce the frequency of injections to one per week
If your child is prescribed a GLP-1 medication, our pharmacists are here to help you use it safely and effectively
Either way, covered patients end up getting the short end of the stick
Some people then move to a maintenance plan